

FOI – 2535

25<sup>th</sup> July 2024

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

I am analysing the usage of new biologic and targeted medications within dermatology medicine. Could you please answer the following question:

How many patients were treated in June 2024 (or latest available month) by the Dermatology department with the following drugs:

- **Abrocitinib (Cibinqo)**
- **Baricitinib (Olmiant)**
- **Dupilumab (Dupixent)**
- **Lebrikizumab (Ebglyss)**
- **Omalizumab (Xolair)**
- **Tralokinumab (Adtralza)**
- **Upadacitinib (Rinvoq)**

### **Response:**

- Abrocitinib (Cibinqo) - 1
- Baricitinib (Olmiant) - 1
- Dupilumab (Dupixent) - 117
- Lebrikizumab (Ebglyss) - 0
- Omalizumab (Xolair) - 37
- Tralokinumab (Adtralza) - 2
- Upadacitinib (Rinvoq) - 20

**Email:** [foi.team@southerntrust.hscni.net](mailto:foi.team@southerntrust.hscni.net)